BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260128
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025751
CREATED:20251119T141849Z
LAST-MODIFIED:20251204T124644Z
UID:42408-1769558400-1769731199@www.pharmajournalist.com
SUMMARY:10th Tumor Models Summit San Francisco
DESCRIPTION:Join the West Coast’s premier pharma and biotech gathering\, the 10th Tumor Models Summit San Francisco\, where innovation meets opportunity in tumor modeling. \nAs the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies\, the oncology landscape is transforming. Exciting modalities like ADCs\, bispecifics\, T-cell engagers demand smarter\, more predictive models. CRISPR and AI are accelerating patient-derived model development at unprecedented speed. \nThis meeting unites industry leaders with cutting-edge vendors to navigate this pivotal shift. Network with pioneers shaping the future of optimizing model selection strategy\, discover breakthrough technologies\, and position your pipeline ahead of the curve. The industry is evolving; the time is now to be part of the conversation. \nDownload the full event guide to find out more: https://ter.li/phkowi
URL:http://www.pharmajournalist.com/event/10th-tumor-models-summit-san-francisco/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point St\, San Francisco\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025751
CREATED:20251204T125152Z
LAST-MODIFIED:20251204T125420Z
UID:42534-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:6th Age-Related Disease Therapeutics Summit
DESCRIPTION:The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. \nOver three days\, the summit brings together senior decision-makers from biopharma\, biotech innovators\, investors\, and academic researchers to accelerate the development and commercialization of next-generation therapeutics. \nAs the aging population grows\, the demand for interventions that extend healthspan and treat chronic conditions is at an all-time high. This meeting provides a unique platform for professionals to explore cutting-edge science\, clinical progress\, and translational strategies shaping this rapidly evolving field. \nFrom senolytics and cellular rejuvenation to mitochondrial health and systemic inflammation\, the summit covers the most promising approaches in age-related disease treatment. \nKey highlights include: \n\nDeep-dive sessions on therapeutic targets\, biomarker validation\, and regulatory pathways.\nInvestment & Funding Insights: Hear from leading investors and strategists on where capital is flowing in longevity and age-related disease innovation.\nNetworking Opportunities: Connect with C-suite executives\, R&D leaders\, and pioneering scientists driving breakthroughs in aging biology.\n\nHere are just some of the ground-breaking companies that will be presenting this year: \nAge 1 | BioAge Labs | Biolexis Therapeutics | Gordian Biotechnology | Insilico Medicine | Juvenescence | Kendall Capital Partners | Novartis | Rubedo Life Sciences | Telocyte \nFind out more\, here: https://ter.li/b3tokv
URL:http://www.pharmajournalist.com/event/6th-age-related-disease-therapeutics-summit-2026/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point Street\, San Francsico\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025751
CREATED:20251111T143842Z
LAST-MODIFIED:20251111T143842Z
UID:42373-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:5th mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe\, scalable\, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its fifth year in Berlin from 27 – 29 January 2026\, this essential meeting unites 170+ senior leaders across R&D\, CMC (Chemistry\, Manufacturing\, and Controls)\, Regulatory Affairs\, Clinical Development\, and Business Strategy from Europe and around the globe. \nThe summit provides a comprehensive\, end-to-end program\, featuring never-before-seen preclinical and clinical data from industry trailblazers such as Moderna\, AstraZeneca\, and BioNTech. The agenda is meticulously structured to address the field’s most pressing challenges and opportunities: broadening mRNA’s scope beyond infectious disease vaccines into oncology\, rare diseases\, and beyond; overcoming the key bottleneck of targeted and tissue-specific delivery; and resolving complex CMC and stability hurdles for next-generation modalities like self-amplifying RNA (saRNA) and circular RNA (circRNA). \nNew for 2026 is a dedicated Gene Editing Focus Day\, highlighting how mRNA technology enables safer\, transient editing strategies and exploring its translational potential in regenerative indications. Attendees will gain actionable\, exclusive insights on critical topics including advanced LNP and polymeric delivery systems\, manufacturing scale-up\, and the integration of AI into mRNA design. \nAdditionally\, the summit offers high-profile investor sessions\, providing candid perspectives on the clinical milestones\, strategic proof points\, and investment signals necessary to make an mRNA platform fundable in today’s competitive landscape. By fostering collaboration and sharing best practices\, the 5th mRNA-Based Therapeutics Summit Europe is the premier platform to de-risk development pipelines and ensure the next generation of revolutionary mRNA medicines successfully reach patients. \nTo know more visit: https://ter.li/t3lsz2
URL:http://www.pharmajournalist.com/event/5th-mrna-based-therapeutics-summit-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025751
CREATED:20251111T142519Z
LAST-MODIFIED:20251111T142519Z
UID:42360-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:4th Molecular Glue Drug Development Summit
DESCRIPTION:Molecular glues are leading the charge in the race to drug the previously undruggable\, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting\, the 4th Molecular Glue Drug Development Summit brings top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues\, this meeting will provide actionable strategies to accelerate the development of safer\, more selective candidates toward the clinic. \nAttendees will explore cutting-edge topics including target selection principles\, rational design frameworks\, sensitive assay technologies\, lead optimization\, and AI/ML approaches for rapid and reliable glue discovery. Delve into emerging frontiers in non-degrading molecular glues and approaches outside oncology to unlock new therapeutic modalities\, expand glues to novel indications\, and stay ahead of the curve in the glues space. \nIf you’re looking to lead the way in the molecular glue space\, connect with the brightest minds\, and gain practical insights to drive programs forward – this is your chance to solve the field’s unique challenges and shape the next wave of innovative therapies. \nExplore the 3 day event guide: https://ter.li/rhdyz0
URL:http://www.pharmajournalist.com/event/4th-molecular-glue-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025751
CREATED:20251104T084713Z
LAST-MODIFIED:20251104T100827Z
UID:42309-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:7th RNAi-Based Therapeutics Summit
DESCRIPTION:2025 is proving to be a landmark year for RNAi. From Alnylam’s first approval in hemophilia to Novartis’ $1.2 billion acquisition of Avidity Biosciences and GSK diving into COPD with an $85 million siRNA licensing deal\, the headlines haven’t stopped. RNAi is officially outgrowing its liver roots and entering a new era of therapeutic expansion. \nWith so much momentum shaping the RNAi landscape\, there’s never been a more pivotal time for the community to come together. The 7th RNAi-Based Therapeutics Summit (January 27-29\, 2026 | Boston\, MA) is the industry-dedicated forum uniting the entire RNAi ecosystem from discovery and complex chemistry to clinical development and CMC. \nLearn more in the official event program here: https://ter.li/8c4zw3 \nThrough 30+ expert-led sessions\, explore how pioneers are moving beyond the liver to unlock new disease frontiers: \nExpanding Horizons to Systemic & Extrahepatic Diseases: \nReprogram metabolic health with dual-targeting siRNA for obesity and leverage multi-gene silencing miRNA to overcome chemo-resistance\, moving beyond appetite suppression and single-target inhibition for durable\, tissue-specific efficacy. \nBreaking Barriers in Brain & CNS Delivery: \nOvercome the blood-brain barrier with Trojan Horse formulations and intrathecal delivery to achieve significant protein knockdown in neurodegenerative diseases\, paving a clear path toward clinical development for severe neurological disorders. \nExamining Innovative Delivery Strategies for Enhanced Targeting: \nUtilize novel ligand platforms\, antibody conjugates\, and DNA origami nanostructures to achieve precise delivery to muscle\, kidney\, and adipose tissue\, optimizing cellular uptake and endosomal escape to avoid the limitations of conventional LNPs. \nEngineering Specificity & Safety Through Chemical Biology: \nApply advanced phosphorothioate patterns and 2′-modifications to transcend GalNAc\, actively directing biodistribution and improving therapeutic indices to build safer\, more precise RNAi drugs. \nOptimizing CMC & Formulation for Commercial Readiness:  \nAddress the unique synthesis\, characterization\, and manufacturing challenges of complex conjugates and novel chemistries to ensure quality\, stability\, and scalability for clinical and commercial supply. \nJoin discovery to clinical development teams from the top pharma and biotechs to de-risk your path to the clinic and accelerate your extrahepatic pipeline. \nWant to find more about registration options? Follow this link to go to the registration platform on our website: https://ter.li/n7bmw8
URL:http://www.pharmajournalist.com/event/7th-rnai-based-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025751
CREATED:20251007T061903Z
LAST-MODIFIED:20251009T110319Z
UID:42127-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:4th Ophthalmic Drug Delivery Summit
DESCRIPTION:With global cases of AMD\, DME\, and glaucoma rapidly increasing\, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However\, poor treatment adherence\, invasive procedures\, and adverse side effects continue to limit therapeutic success\, highlighting the critical need for optimized delivery approaches. \nRecent developments\, including Genentech’s Susvimo label expansion\, advances in sustained-release and suprachoroidal delivery systems\, and Regeneron’s acquisition of Oxular\, demonstrate a growing industry focus on improving durability and reducing invasiveness. \nThat’s why 80+ industry leaders will gather at the 4th Ophthalmic Drug Delivery Summit this January to explore long-acting intravitreal and subretinal innovations\, emerging suprachoroidal techniques\, novel formulation strategies\, drug-device integration\, and evolving regulatory expectations. \nJoin experts across preclinical and clinical R&D\, formulation\, pharmacology\, devices\, and combination products for three days of focused discussions driving the future of safe\, effective\, and durable ophthalmic therapies. \nDownload the full event guide to find out all the topics to be discussed and the full expert speaker faculty: https://ter.li/vz7y60
URL:http://www.pharmajournalist.com/event/4th-ophthalmic-drug-delivery-summit/
LOCATION:Hilton San Francisco Financial District\, 750 Kearny St\, San Francisco\, CA\, 94108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025751
CREATED:20251003T101634Z
LAST-MODIFIED:20251003T101634Z
UID:42113-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:Non-Opioid Pain Therapeutics Summit
DESCRIPTION:The race to deliver safe\, effective non-opioid pain therapeutics has never been more urgent – or more achievable. After decades of setbacks\, the field is achieving long-awaited progress with recent regulatory approvals from Tonix and Vertex\, strategic acquisitions from Eli Lilly\, and late-stage successes validating the commercial potential of novel mechanisms. \nHowever\, the clinical pathway for pain remains one of the most challenging in drug development\, requiring smarter trial design\, validated endpoints\, patient stratification strategies\, and strong regulatory engagement. \nThe Inaugural Non-Opioid Pain Therapeutics Summit is the only meeting dedicated to overcoming the unique scientific and clinical barriers in pain drug development. Discussions will focus on optimizing trial design in chronic pain\, advancing mechanism-specific biomarkers\, addressing placebo response and patient stratification\, and aligning with regulators on validated endpoints. \nWith case studies spanning NaV inhibitors\, novel receptor targets\, and first-in-class modalities\, the summit provides the scientific depth and clinical perspective required to move non-opioid pain candidates successfully through the pipeline. \nAttendees will be learning from companies with approvals such as Tonix\, exploring late-stage strategies from innovators like Latigo and Algiax\, and uncovering discovery breakthroughs from Nocion and Axonis. Join 70+ discovery\, preclinical\, translational and clinical industry-based experts driving the future of non-opioid pain therapies across diverse pain indications. \nTo know more visit: https://ter.li/h7pe87
URL:http://www.pharmajournalist.com/event/non-opioid-pain-therapeutics-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251209
DTEND;VALUE=DATE:20251211
DTSTAMP:20260515T025751
CREATED:20251009T103909Z
LAST-MODIFIED:20251009T103909Z
UID:42161-1765238400-1765411199@www.pharmajournalist.com
SUMMARY:7th CNS Drug Delivery Summit
DESCRIPTION:Unlocking Safer\, More Efficient Delivery to Targeted Brain Regions by Advancing Direct\, & Systemic Delivery to the CNS Via TfR1 & Beyond \nDespite milestones such as Roche’s Trontinemab Brainshuttle™ achieving robust amyloid clearance\, challenges remain in reaching targeted brain regions\, improving predictive modelling\, ensuring efficacy and penetrance\, and developing safer\, targeted delivery approaches. \nJoin 100+ industry experts spanning neuroscientists\, chemists\, device engineers\, conjugation scientists\, DMPK experts\, delivery specialists\, and more at the 7th CNS Drug Delivery Summit to collaborate\, network\, and learn cutting-edge strategies that are tackling the unique challenges in gaining access to the brain. \nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/7th-cns-drug-delivery-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251209
DTEND;VALUE=DATE:20251212
DTSTAMP:20260515T025751
CREATED:20250919T115220Z
LAST-MODIFIED:20250919T115220Z
UID:42013-1765238400-1765497599@www.pharmajournalist.com
SUMMARY:2nd ADC Pharmacokinetics & Clinical Pharmacology Summit
DESCRIPTION:With the launch of the FDA’s Project Optimus\, and the evolving clinical pharmacology guidelines for ADCs\, the need to identify an optimal clinical dose that balances safety with efficacy has never been more evident. \nBringing together a focused audience of clinical pharmacology\, PK\, pharmacometrics\, modelling\, and bioanalysis specialists\, the 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit returns to Boston December 9-11\, 2025. \n\nInvestigate non-traditional payloads and bispecific ADCs to understand how unique PK properties influence clinical outcomes with AstraZeneca & Tavotek\nExplore dose optimization and adjustment through modelling and simulation\, with Astellas\nJoin Abbvie & Daiichi Sankyo to use bioanalytical methods to assess structural integrity and DAR for deeper insights into drug clearance\nApply QSP platforms with Novartis to rigorously evaluate the predictive value of computational modelling\nLeverage AI and enhance ADME parameter understanding with Sutro Biopharma & University at Buffalo\n\nSee the event guide: https://ter.li/vrojuh
URL:http://www.pharmajournalist.com/event/2nd-adc-pharmacokinetics-clinical-pharmacology-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251208
DTEND;VALUE=DATE:20251211
DTSTAMP:20260515T025751
CREATED:20251003T095343Z
LAST-MODIFIED:20251003T095343Z
UID:42107-1765152000-1765411199@www.pharmajournalist.com
SUMMARY:LEAP TD: Life Sciences
DESCRIPTION:As biopharma organizations decrease their budgets and move away from a recruitment-centric approach\, the need to develop existing talent to fill key technical skills gaps has never been more mission critical. \nThis December in Boston\, LEAP TD: Life Sciences will bring together senior talent development leaders from across biopharma to explore how learning and development can directly support scientific progress and organizational resilience. \nJoin 60+ senior L&D\, HR\, and training leaders from top biotech and pharma organizations to transform your L&D strategy to develop and retain a highly skilled\, agile scientific while building a resilient leadership pipeline to accelerate innovative research and development. This is your opportunity to rethink how learning\, leadership\, and a renewed focus on strategic workforce planning can drive measurable business impact\, commercial\, and scientific success. \nHow will attending help you? \n\nAccelerate workforce readinessby designing learning interventions that evolve with AI\, automation\, and cutting-edge scientific advancements\nBridge critical talent gapsthrough career pathways that upskill teams in biomanufacturing\, regulatory science\, and data fluency\nEmpower future-ready leaderswith the capabilities to navigate complexity\, drive innovation\, and lead transformational change\n\nAttending companies include Bristol Myers Squibb\, Vertex Pharma\, Biogen\, Labcorp\, Kyowa Kirin\, Arcus Biosciences\, Takeda\, and many other leading biotech and pharma organizations. \nThrough focused case studies and peer-led discussions\, attendees will uncover how leading teams are embedding development into the daily realities of regulated environments\, enabling leadership at every level\, and designing learning experiences that reflect the complexity of life sciences work. Whether you’re building scalable mentorship programs\, rethinking onboarding for scientific roles\, or aligning development with compliance and innovation goals\, this is your opportunity to connect with peers facing similar challenges and leave with strategies that drive measurable impact. \nThis is not another L&D expo. It’s a strategic\, high-level forum where talent development\, training\, and L&D leaders working in life sciences come together to discuss their talent development challenges and uncover new strategies in a collaborative environment. \nTo learn more about the event and find out whether this is the event that you need to take your biopharma workforce to the next level\, view the event brochure here: https://ter.li/jyi8dj.
URL:http://www.pharmajournalist.com/event/leap-td-life-sciences/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251203
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025751
CREATED:20250827T112407Z
LAST-MODIFIED:20250827T112407Z
UID:41782-1764720000-1764892799@www.pharmajournalist.com
SUMMARY:14th Tumour Models Summit London
DESCRIPTION:With the European oncology market increasingly focused on emerging modalities\, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody\, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions\, there has never been a more important year to stay up to date with the latest innovations in tumour modelling. \nAs the longest-standing forum from the world-renowned Tumour Models event series\, the 14th Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma\, biotech\, and model providers from across the UK and Western Europe to soundboard recent model selection strategies with the goal of bridging the translational gap to the clinic. \nDownload the event guide for full details: https://ter.li/hsztzb
URL:http://www.pharmajournalist.com/event/14th-tumour-models-summit-london/
LOCATION:Park Plaza Victoria London\, 239 Vauxhall Bridge Road Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025751
CREATED:20250805T115734Z
LAST-MODIFIED:20250805T120701Z
UID:41643-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond\, the field has grown from strength to strength. With a surge of billion-dollar investments\, the release of new groundbreaking data\, and recent real-world clinical progression\, the autoimmune cell therapy field is poised for clinical and commercial success. \nThe 3rd Cell Therapy for Autoimmune Disease Summit (December 2-4 | Philadelphia\, PA) returns at a pivotal time\, providing first-hand insights and case studies needed to keep your team ahead in this fast-evolving space. Reconnect with 130+ scientific pioneers\, with expertise spanning CAR-T\, Treg\, in vivo and NK cell therapies\, as they unveil the latest clinical data and cutting-edge innovations redefining the chronic care of autoimmune indications. \nAccess Your Brand-New 2025 Agenda Copy! \nLearn directly from industry titans including Cabaletta Bio\, Kyverna Therapeutics\, Umoja Biopharma\, Cartesian Therapeutics\, Century Therapeutics\, Artiva Biotherapeutics and Novartis\, to benchmark your current strategies and gain a competitive edge amongst your peers to accelerate your lead candidate from preclinical innovation to clinical success. \nWhether you are preparing for your first clinical trials\, or making the transition into later phases\, our carefully curated two-tracked agenda (now expanded to the Workshop Day!) has content tailored for you. \n\nPreclinical & Translational: Address challenges in antigen selection\, delve into autologous and allogeneic translational strategies\, and discuss alternatives to B-cell depletion\, to bring the next wave of therapies to the clinic.\nClinical: Unpack trial design\, evaluate long-term clinical outcomes\, share regulatory strategies\, and learn how to operationalize studies for broader patient access.\n\nWith cell therapy companies increasingly targeting autoimmune diseases\, and autoimmune companies continuing to embrace cellular approaches\, ensure you join the industry’s definitive meeting committed to transforming the promise of cell therapies in autoimmunity into reality. \nEvent Guide | Register | Learn More
URL:http://www.pharmajournalist.com/event/3rd-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sheraton Philadelphia Downtown\, 201 N 17th Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025751
CREATED:20250919T105408Z
LAST-MODIFIED:20250919T105408Z
UID:41976-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:6th Gene Therapy for Ophthalmic Disorders Summit
DESCRIPTION:The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh\, North Carolina\, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye diseases. With irreversible vision loss progressing rapidly in many conditions\, gene therapy continues to emerge as a critical one-time intervention that can preserve and restore sight for patients in need. \nMomentum in 2025 is stronger than ever. Kriya Therapeutics is advancing its preclinical pipeline\, Opus Genetics and SpliceBio are progressing into early trials\, while Ocugen\, 4D Molecular Therapeutics\, and AbbVie are racing toward BLA approval. Against this backdrop of progress\, challenges around endpoint selection\, funding strategies\, and safe delivery methods remain at the forefront. The summit provides a unique platform to tackle these issues head-on and drive forward meaningful breakthroughs. \nAttendees will gain access to exclusive data and insights\, including preclinical updates from Opus Genetics\, Coave Therapeutics\, and Axovia Therapeutics\, alongside pivotal 2025 clinical progress shared by Ocugen\, Adverum Biotechnologies\, and Beacon Therapeutics. A major highlight is the Interview the Investor session with James Kasuboski\, Partner & Head of Research at Luma Group\, where attendees will hear directly from investors on the criteria shaping ophthalmic gene therapy funding and strategies for building sustainable development approaches. \nAdditional sessions will spotlight patient-led regulatory engagement\, comparative analyses of delivery approaches\, and strategies for optimizing trial design and patient retention. With a carefully balanced agenda – equally split between preclinical and clinical content – this meeting provides a comprehensive view of the ophthalmic gene therapy pipeline. \nFeaturing 18+ senior expert speakers\, 3+ hours of clinical data\, 2+ hours of preclinical research\, and 6+ hours of networking opportunities\, the summit unites biopharma leaders\, investors\, and innovators to accelerate progress from IND through to late-stage clinical development. \nJoin us in Raleigh to connect with decision-makers across the ophthalmic gene therapy value chain\, uncover the next wave of breakthroughs beyond Luxturna\, and ensure your therapy reaches patients faster. \n View the full event program on our website here: https://ter.li/0duhtz
URL:http://www.pharmajournalist.com/event/6th-gene-therapy-for-ophthalmic-disorders-summit/
LOCATION:DoubleTree by Hilton Raleigh Midtown\, 2805 Highwoods Blvd\, Raleigh\, NC\, 27604\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025751
CREATED:20250905T114029Z
LAST-MODIFIED:20250905T114054Z
UID:41892-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:5th Applied Biocatalysis & Enzyme Engineering Summit
DESCRIPTION:Navigate New FDA Leadership\, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical\, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & Market \nWith major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes\, new FDA draft guidance on post-approval CMC\, and potency assays facing heightened scrutiny\, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum\, with ANVISA and Health Canada joining harmonization initiatives\, and ICH Q12 implementation for CGTs underway. \nThe 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington\, D.C. for real-world case studies\, insights from regulators\, and deep dives into IND-to-BLA planning\, global alignment\, and emerging modalities. \nIf you’re navigating nonclinical\, clinical\, or CMC submissions\, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond. \nLearn more: https://ter.li/c211fx
URL:http://www.pharmajournalist.com/event/5th-applied-biocatalysis-enzyme-engineering-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T025751
CREATED:20250905T112712Z
LAST-MODIFIED:20250905T112817Z
UID:41881-1764633600-1764806399@www.pharmajournalist.com
SUMMARY:Designing the AI-Enabled Biopharma Workforce Summit
DESCRIPTION:The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences\nMost roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how that transformation manifests itself\, in what jobs\, with what skills\, and across what proportion of our workforces is not yet fully clear. \nWhat is clear\, though\, is that the future depends on what we do now. The most forward-thinking companies already know that innovation doesn’t just happen at the bench\, it also takes place company-wide in working out what needs to be done\, how\, and by whom. \nThey are building future workforce capability faster by reassessing the needs of each department and fundamentally rethinking what work is best done by people versus what can be automated with technology. For the first time\, this forum will shine a light on how this is done. \nTaking part will help you approach organizational design with a new perspective which is skills centric\, rather than job centric and allow you to walk away with a new skills taxonomy that will help you deliver more productivity and more innovation from fewer people in less time. \nDownload the Agenda
URL:http://www.pharmajournalist.com/event/designing-the-ai-enabled-biopharma-workforce-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025751
CREATED:20250829T120338Z
LAST-MODIFIED:20250829T120338Z
UID:41820-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Regulatory Affairs Summit
DESCRIPTION:With major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes\, new FDA draft guidance on post-approval CMC\, and potency assays facing heightened scrutiny\, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum\, with ANVISA and Health Canada joining harmonization initiatives\, and ICH Q12 implementation for CGTs underway. \nThe 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington\, D.C. for real-world case studies\, insights from regulators\, and deep dives into IND-to-BLA planning\, global alignment\, and emerging modalities. \nIf you’re navigating nonclinical\, clinical\, or CMC submissions\, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond. \nFind out more: https://ter.li/c211fx
URL:http://www.pharmajournalist.com/event/2nd-cell-gene-therapy-regulatory-affairs-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025751
CREATED:20250820T122909Z
LAST-MODIFIED:20250820T122909Z
UID:41738-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:2nd Innovation in Obesity Therapeutics Summit
DESCRIPTION:The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry\, including Novo Nordisk\, Eli Lilly and Boehringer Ingelheim\, who will share their groundbreaking research and strategies. The pressure is on to develop best-in-class treatments that transform patient lives. \nDon’t miss this pivotal opportunity to network with 60+ experts in the field of obesity\, forge crucial collaborations\, and be part of the solution. \nFind out more here: https://ter.li/vnapww
URL:http://www.pharmajournalist.com/event/2nd-innovation-in-obesity-therapeutics-summit/
LOCATION:DoubleTree by Hilton Hotel San Diego – Mission Valley\, 7450 Hazard Center Dr\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025751
CREATED:20250812T104500Z
LAST-MODIFIED:20250812T104500Z
UID:41714-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:8th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs\, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative\, cancer and rare disorders. In 2025 alone\, the field has seen major collaborations\, including Wayfinder Biosciences with Daiichi Sankyo\, Ono Pharmaceutical with Reborna Biosciences\, and xFOREST with Astellas Pharma—signaling growing momentum and industry confidence. \nNow in its 8th year\, the RNA-Targeted Drug Discovery & Development Summit returns as the only dedicated industry forum addressing the unique challenges of RNA-targeted drug development across splice modulators\, covalent drugs\, proximity inducers and direct RNA binders.\nJoin 25+ world-class speakers from leaders like PTC Therapeutics\, ReviR Therapeutics\, Remix Therapeutics\, Rgenta Therapeutics\, Arrakis Therapeutics and more this December to gain the connections\, tools and scientific firepower needed to bring your RNA-targeted therapeutics to clinic and beyond. \nStep into the future of RNA-targeted drugs at the 8th RNA-Targeted Drug Discovery & Development Summit. With 75% new speakers from 2024 and 50% of the speakers sharing new data\, this summit is set to offer the latest data and fresh insights on small molecules targeting RNA. \nThis year\, join 80+ experts in RNA biology\, drug discovery\, medicinal chemistry\, and structural biology to gain the latest data on visualizing dynamic RNA structures\, identifying functional binders\, improving selectivity\, enhancing delivery stability and achieving oral bioavailability. \nWhether you’re focused on RNA splice modulators\, covalent binders\, proximity inducing drugs\, or direct RNA binders this event will give you the tools and insights to fast track the discovery of functional binders and accelerate your pipeline of RNA-targeted small molecules to the clinic. \nConnect with your global community at the world’s only meeting for RNA-targeted drug experts. \nTo know more visit: https://ter.li/rcvdor
URL:http://www.pharmajournalist.com/event/8th-rna-targeted-drug-discovery-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251201
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T025751
CREATED:20250820T123645Z
LAST-MODIFIED:20250820T123645Z
UID:41743-1764547200-1764806399@www.pharmajournalist.com
SUMMARY:7th Cell Therapy Analytical Development Summit
DESCRIPTION:Recognized as the industry’s leading forum for cell therapy analytical\, quality control\, assay\, and CMC professionals\, the 7th Cell Therapy Analytical Development Summit\, returns to Boston to provide the expertise needed to prepare your teams for clinical and commercial readiness. Hear directly 80+ experts from Takeda\, Arsenal Bio\, Bayer\, Genentech\, Adicet Bio\, Quell Therapeutics\, and the National Institute of Health\, as they share proven strategies\, innovative technologies and best-in-class approaches to enhance your product safety and quality\, ahead of regulatory approval. \nNow combined with the previously separate\, Cell Therapy Potency Assay Summit\, this meeting provides you with an even more comprehensive agenda\, covering the full landscape of analytical development\, across early- and late-stage assay development tracks. Join us this December to fast-track the next era of safe\, potent and robust cell therapies to market! \nFor more information\, please visit https://ter.li/9uagdj
URL:http://www.pharmajournalist.com/event/7th-cell-therapy-analytical-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251201
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T025751
CREATED:20250812T105107Z
LAST-MODIFIED:20250812T105107Z
UID:41720-1764547200-1764806399@www.pharmajournalist.com
SUMMARY:9th Complement-Based Drug Development Summit
DESCRIPTION:Diving Into the Complement Cascade to Explore Intervention Points\, Harnessing Biomarker Strategies to Identify Optimal Patient Populations\, & Exploring the Therapeutic Opportunity from Rare Disease to Inflammation to Autoimmune Disease. \nSo far\, 2025 has brought significant excitement and progress to the complement-based therapeutic landscape. Leading biopharma companies like Novartis\, Annexon Biosciences and Omeros\, are making significant clinical progress in PNH\, AMD\, IgAN and C3G\, whilst key academics such as Michael Holers\, Michael Brenner\, and Brahm Segal continue to make discoveries in complement imaging\, novel pathways\, and new therapeutics areas such as oncology and transplantation. \nThe Complement-Based Drug Development Summit returns for its 9th year to unite the leading experts in complement biology and therapeutic development\, from innovative biotech to impactful large pharma and academic experts. This meeting will harness the energy and dedication deepening the current understanding of the complement system to advance drug development in rare disease and beyond with patients at the forefront. \nJoin us at the 2025 meeting to gain insights from 20+ expert speakers covering the end-to-end complement-based drug development\, from basic biology to diagnostics and clinical development. \nParticipate in three dedicated workshops for active discussion on key topics including the intracellular complement system\, bispecific complement mediators\, and innovative delivery of complement-based therapeutics to ensure delivery to the correct targets. \nThis comprehensive program spans a broad spectrum of renal\, ophthalmic\, neurological\, and haematological indications\, mirroring the shift in focus of the complement field from rare orphan indications to larger patient populations. \nJoin 80+ industry experts this December and access exclusive insights into therapeutic development across the complement field and bring actionable learnings and competitive intelligence back to your team.
URL:http://www.pharmajournalist.com/event/9th-complement-based-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251119
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025751
CREATED:20250829T114330Z
LAST-MODIFIED:20250829T114330Z
UID:41806-1763510400-1763683199@www.pharmajournalist.com
SUMMARY:3rd Donor Selection & Cell Source Summit
DESCRIPTION:Returning for its third year\, the Donor Selection & Cell Source Summit is the only industry-dedicated forum focused exclusively on the strategic and scientific challenges of donor selection and cell sourcing for allogeneic therapies. \nThis summit brings together leading minds from biopharma\, blood banks\, apheresis providers\, and cell therapy innovators to address one of the most critical bottlenecks in the development of scalable\, off-the-shelf treatments. \nWith over 600 allogeneic clinical trials currently underway\, the pressure to secure high-quality\, consistent donor-derived starting material has never been greater. This summit provides a unique opportunity to explore how smarter donor screening\, recruitment\, and retention strategies can directly impact product quality\, manufacturing scalability\, and clinical success. \nAttendees will gain actionable insights into: \n\nDonor testing and screening protocols that improve product safety and consistency\nRetention strategies to build reliable donor pools\nCryobiology and supply chain innovations that enhance cell viability and streamline logistics\nAnalytical development and quality control for robust characterization of starting material\n\nSee what other insights you can walk-away with in the program: https://ter.li/c2h7ym \nThe summit features expert speakers from leading organizations including Bristol Myers Squibb\, Genentech\, Allogene Therapeutics\, ImmuneBridge\, NKILT\, Luminary Therapeutics\, and many more offering a cross-functional perspective on how donor and source decisions shape the future of cell therapy. \nUnlike broader cell therapy conferences\, this event zeroes in on the upstream decisions that define downstream success. Whether you’re optimizing donor engagement\, navigating regulatory complexities\, or refining your sourcing strategy\, the Donor Selection & Cell Source Summit provides the tools and connections to move your program forward. \nExpect two days of deep scientific exchange\, strategic discussion\, and collaborative problem-solving in an intimate setting designed to foster meaningful dialogue. If you’re working to unlock the full potential of allogeneic therapies\, this is the one event you can’t afford to miss. \nFor more information on the summit\, view the program: https://ter.li/dc18d1
URL:http://www.pharmajournalist.com/event/3rd-donor-selection-cell-source-summit/
LOCATION:Westin Bayview San Diego\, 1051 Columbia St\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025751
CREATED:20250912T125210Z
LAST-MODIFIED:20250912T130631Z
UID:41941-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:9th Dermatology Drug Development Summit
DESCRIPTION:The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with immuno-inflammatory disease. With disease heterogeneity and biomarker discovery fueling a new wave of research\, and clinical pipelines facing intensifying competition\, the need to develop differentiated\, novel candidates has never been more critical. \nAs the field accelerates with clinical and commercial momentum\, highlighted by Sanofi’s continued success with Dupixent\, Corvus’ promising Phase 1 data on Soquelitinib\, and landmark deals such as Gilead’s $1.7B inflammation partnership with LEO Pharma – this summit provides an essential platform to stay ahead of the curve. Returning this November\, the meeting unites 120+ leading experts from pharma\, biotech\, and academia\, all dedicated to overcoming the most pressing R&D bottlenecks in dermatology drug development. \nAttendees will gain insights into the latest preclinical and clinical findings across both rare and common conditions\, including atopic dermatitis\, psoriasis\, hidradenitis suppurativa\, vitiligo\, pemphigus nodularis\, bullous pemphigoid\, and alopecia areata. Sessions will explore the complexity of disease heterogeneity\, emerging mechanisms of action\, safety considerations\, and the evolving regulatory landscape. With contributions from thought leaders at AbbVie\, Sanofi\, Takeda\, Incyte\, Merck\, and other trailblazing organizations\, discussions will span discovery\, preclinical\, translational\, clinical\, and medical affairs perspectives. \nThe program also offers a forward-looking exploration of the modalities reshaping dermatology pipelines\, from bispecifics and biologics to oligonucleotides and beyond. By combining cutting-edge science with real-world clinical and strategic insights\, the 9th Dermatology Drug Development Summit equips participants with the tools to accelerate innovation\, navigate increasing competition\, and ultimately deliver therapies that transform patient quality of life. \nIf you’d like to learn more about the summit\, download the event guide or get in touch!
URL:http://www.pharmajournalist.com/event/9th-dermatology-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025751
CREATED:20250829T120700Z
LAST-MODIFIED:20250829T120700Z
UID:41824-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:7th Myeloid-Directed Therapies Summit
DESCRIPTION:The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology\, Inflammation and Beyond… \nUniting leading experts from pharma\, biotech\, and academia\, the 7th Myeloid-Directed Therapies Summit is the definitive event for anyone developing macrophage- and neutrophil-targeted therapies. As the field pushes beyond T-cells\, this forum dives into myeloid reprogramming\, cell state heterogeneity\, and translational challenges to unlock next-generation immune modulation. \nWith breakthrough insights from Eli Lilly\, AbbVie\, Pfizer\, AstraZeneca\, and Faron Pharmaceuticals\, and cutting-edge academic labs\, this is your opportunity to explore clinical case studies\, dissect failed monotherapy lessons\, and gain clarity on patient stratification\, trial design\, and combination strategies. \nLearn more: https://ter.li/by8e82
URL:http://www.pharmajournalist.com/event/7th-myeloid-directed-therapies-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025751
CREATED:20250731T103150Z
LAST-MODIFIED:20250731T103150Z
UID:41605-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:3rd LNP Characterization & Analytical Development Summit
DESCRIPTION:3rd LNP Characterization & Analytical Development Summit\nDe-Risk Regulatory Submissions Through Smarter LNP Characterization \nCurated in collaboration with leading analytical scientists and key LNP stakeholders\, the 3rd LNP Characterization & Analytical Development Summit returns with new data\, fresh insights\, and an expanded speaker lineup. As the definitive forum for LNP analytics and characterization\, this summit is your go-to platform for driving the development of safe\, effective\, and high-quality LNP-based drug products. \nThis highly focused\, three-day agenda will equip analytical experts with the technical insights needed to: \n\nAccelerate development timelines\nBridge critical analytical gaps\nStreamline regulatory submissions for faster approval\n\nJoin over 90 industry leaders in analytics\, characterization\, assays\, and CMC from organizations including Pfizer\, Novo Nordisk\, Prime Medicine\, Tessera Therapeutics\, GSK\, Sanofi\, and more. \nKey Benefits of Attending: \n\nGain deep technical knowledge on cutting-edge LNP analytics\nDiscover strategies to overcome common characterization challenges\nAlign on regulatory expectations to support faster\, smoother submissions\nNetwork with peers tackling the same development and regulatory hurdles\n\nWith data-driven presentations and expert-led discussions\, this is your opportunity to help define and implement robust analytical strategies that support the rapid development and approval of next-generation genomic medicines. \nLearn more here: https://ter.li/ympfix
URL:http://www.pharmajournalist.com/event/3rd-lnp-characterization-analytical-development-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025751
CREATED:20250731T102550Z
LAST-MODIFIED:20250731T102550Z
UID:41600-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:Model-Informed Drug Development Summit
DESCRIPTION:With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing\, regulatory change is accelerating\, solidifying Model-Informed Drug Development (MIDD) as a critical\, non-negotiable tool in the drug development process. \nThe Model-Informed Drug Development Summit is the first and only industry-focused\, 3-day strategic meeting dedicated to exploring how MIDD is transforming decision-making and driving drug development success. This is your opportunity to benchmark against industry leaders\, refine your strategy\, and future-proof your development approach. \nJoin senior experts in pharmacometrics\, clinical pharmacology\, PK/PD\, and modeling from leading organizations including Pfizer\, Third Rock Ventures\, Johnson & Johnson\, AbbVie\, and more\, as they uncover how MIDD is being used to: \n\nSelect better candidates earlier in development\nStreamline or eliminate clinical trial phases\nPersonalize and optimize trial designs\nBuild stronger\, data-driven regulatory submissions\n\nWhy Attend? \n\nUnlock real-world case studies showing how MIDD accelerates timelines\, cuts costs\, and improves outcomes\nGain insight into how peers are implementing MIDD from discovery through to regulatory approval\nCollaborate with cross-functional teams to exchange strategies and overcome shared challenges\n\nWith exclusive insights into ICH M15\, practical applications across diverse therapeutic areas\, and proven examples of success\, this summit is your one-stop shop for unleashing the full potential of MIDD. \nLearn more here: https://ter.li/unljt8
URL:http://www.pharmajournalist.com/event/model-informed-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251117
DTEND;VALUE=DATE:20251120
DTSTAMP:20260515T025751
CREATED:20250905T113422Z
LAST-MODIFIED:20250905T113422Z
UID:41887-1763337600-1763596799@www.pharmajournalist.com
SUMMARY:9th Antifibrotic Drug Development Summit
DESCRIPTION:2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s\, Boehringer’s Phase 3 IPF data\, Stanford’s TGF-β work in cardiovascular fibrosis\, to over $3B in deals from Lilly\, GSK\, and others\, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift. \nThat’s why this year’s Antifibrotic Drug Development Summit is THE place to be this November.  Learn from the industry’s premier experts at the forefront of fibrosis research\, gain unmissable cross-fibrosis insights\, and make unmatched connections with 80+ industry leaders from Pfizer\, Eli Lilly\, Novartis\, Takeda and more! \nAccess this year’s incredible lineup of speakers \nJoin us this year to: \n\nUnlock novel targets with advances in single-cell and spatial omics\, immune-stromal interactions\, and cross-tissue mechanisms\, featuring insights from Harvard Medical School\, Gilead Sciences\, and AdaptVac\nStrengthen translational confidence with precision-cut tissue slices\, 3D models\, and AI-driven biomarker strategies to bridge the gap between preclinical promise and clinical success\nDesign winning clinical programs with lessons from recent Phase 2 data\, including Resmetirom’s approval for MASH fibrosis and emerging IPF signals from GRI Bio and Redx Pharma\nNavigate the evolving landscape with expert perspectives on combination therapies\, GLP-1 competition\, and investor priorities to position your pipeline for partnerships and approvals\n\nDon’t miss out – invite your colleagues to join you and take advantage of our early bird rates and group savings! \nSecure my spot
URL:http://www.pharmajournalist.com/event/9th-antifibrotic-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251111
DTEND;VALUE=DATE:20251114
DTSTAMP:20260515T025751
CREATED:20250829T114659Z
LAST-MODIFIED:20250829T114659Z
UID:41812-1762819200-1763078399@www.pharmajournalist.com
SUMMARY:7th TIL Therapies Summit
DESCRIPTION:Now in its seventh year\, the TIL Therapies Summit returns as the leading event dedicated to advancing tumor-infiltrating lymphocytes (TIL) therapies. Taking place November 11–13\, 2025\, in Boston (MA)\, this summit unites global experts across biopharma\, academia\, clinical practice\, and manufacturing to accelerate the development and commercialization of next-generation TIL treatments. \nFollowing the first-ever FDA approval of a TIL therapy in the U.S.\, and with regulatory decisions pending in Canada and Europe\, the field is at a pivotal inflection point. The 7th TIL Therapies Summit offers a timely platform to explore how optimized TIL selection\, engineering\, and manufacturing can unlock scalable\, potent treatments for solid tumors beyond melanoma. \nThe program is designed to tackle the most pressing challenges in TIL development\, including: \n\nEngineering TILs for improved persistence\, potency\, and specificity\nManufacturing innovations in closed systems to speed-up turnaround\, and reduce IL-2 dependency\nClinical trial design and patient access strategies\nBiomarker discovery and potency assay development\nReal-world implementation and patient/provider perspectives\n\nWith 28+ expert speakers\, 50+ attendees\, and 8 hours of dedicated networking\, the summit fosters a collaborative environment for sharing cutting-edge science\, operational insights\, and lived experiences. Attendees will hear from leading voices including: \n\nInge Jedema\, Netherlands Cancer Institute\nJingwei Sun\, Grit Biotechnology\nMadan Jagasia\, Obsidian Therapeutics\nMicah Benson\, KSQ Therapeutics\nMichael Lotze\, University of Pittsburgh\nRoda Amaria\, MD Anderson Cancer Center\n\nYou can see who else is speaking in this year’s program: https://ter.li/i4a730 \nWhether you’re preparing for your first clinical trial\, scaling manufacturing\, or navigating regulatory pathways\, this summit delivers actionable insights for every stage of the TIL pipeline. Two new tracks focused on R&D and CMC ensure that both scientific and operational teams gain maximum value. \nUnlike broader cell therapy events\, the TIL Therapies Summit offers a focused\, intimate setting where attendees can engage in meaningful dialogue\, build lasting partnerships\, and stay ahead of the curve in this rapidly evolving space. \nIf you’re committed to transforming the treatment landscape for solid tumors\, the 7th TIL Therapies Summit is your must-attend event for 2025. \nFind out more here: https://ter.li/nfdnks
URL:http://www.pharmajournalist.com/event/7th-til-therapies-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251110
DTEND;VALUE=DATE:20251113
DTSTAMP:20260515T025751
CREATED:20250703T134927Z
LAST-MODIFIED:20250703T134927Z
UID:41451-1762732800-1762991999@www.pharmajournalist.com
SUMMARY:7th Targeted Radiopharmaceuticals Summit Europe
DESCRIPTION:7th Targeted Radiopharmaceuticals Summit Europe \n10–12 November 2025 | Amsterdam \nTranslating Novel Radiopharmaceutical Therapies to Transform the Medical Future \n \nNow in its seventh year\, the Targeted Radiopharmaceuticals Summit Europe returns to Amsterdam to bring together over 200 leaders in radiopharmaceutical therapy development. Designed to establish radiopharmaceuticals as a core pillar of oncology\, this event is essential for professionals working across discovery\, clinical development\, and manufacturing. \nHighlights of the 2025 Program: \nMore than 45 expert speakers from leading companies including Bayer\, AstraZeneca\, Novartis\, Telix Pharmaceuticals\, and more\nIntroduction of a third content track\, covering:\nDiscovery & Preclinical\nTranslational & Clinical\nCMC & Sourcing\nSix in-depth workshops on key challenges including radiopharmaceutical design\, dosimetry translation\, and isotope supply \nKey Speakers: \nThomas Birger Eden-Jensen\, Head\, External Supply Management TRP\, Bayer\nMark Fielding\, Director\, CMC\, Regulatory Affairs\, TRP\, AstraZeneca NEW SPEAKER\nIsabel Jaco\, Group Leader\, RLT Drug Discovery\, Novartis NEW SPEAKER\nSandra Uhlenbroich\, Director\, Discovery\, Bicycle Therapeutics NEW SPEAKER\nFrederic Fantino\, Global Medical Affairs EMEA\, Telix Pharmaceuticals NEW SPEAKER\nThijs Spoor\, Chief Executive Officer\, Perspective Therapeutics NEW SPEAKER\nSigal Kalmanson\, Chief Executive Officer\, Starget Pharma \nTopics Include: \nNovel target discovery\, including SSTR3 and FAP\nIsotope selection and supply chain resilience\nTranslating dosimetry into clinical studies\nFirst-in-human study design and Phase 0 considerations\nScalable and compliant manufacturing strategies \nThis is the most comprehensive European agenda for targeted radiopharmaceuticals to date\, built to accelerate asset development and address the sector’s most pressing challenges. \nView the full program: https://ter.li/gowcuf \nHyperlink – https://ter.li/gowcuf
URL:http://www.pharmajournalist.com/event/7th-targeted-radiopharmaceuticals-summit-europe/
LOCATION:Mövenpick Hotel Amsterdam City Centre\, Piet Heinkade 11\, Amsterdam\, 1019 BR\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251110
DTEND;VALUE=DATE:20251112
DTSTAMP:20260515T025751
CREATED:20250610T104455Z
LAST-MODIFIED:20250610T111651Z
UID:41230-1762732800-1762905599@www.pharmajournalist.com
SUMMARY:Transdermal and Microneedle Drug Delivery
DESCRIPTION:Have you considered how microneedle drug delivery systems could revolutionise the future of vaccine and drug administration? \nThis November\, join SAE Media’s 4th Annual Transdermal and Microneedle Drug Delivery Conference. Engage with leading drug development and delivery experts in a dynamic\, expert-led environment. Connect with forward-thinking innovators to explore cutting-edge case studies\, breakthrough vaccine and therapeutic applications\, and the evolving capabilities of transdermal and microneedle technologies. Transdermal and microneedle patches hold the potential to ‘go beyond the needle’ and transform pharmaceutical development—offering enhanced accessibility and long-term delivery solutions. With applications ranging from improved vaccine distribution to advanced diagnostics\, these technologies are poised to reshape healthcare by increasing efficacy and expanding global access to life-changing treatments. \nTo know more click here.
URL:http://www.pharmajournalist.com/event/transdermal-and-microneedle-drug-delivery-2025/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:marketingteamlondon@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251109
DTEND;VALUE=DATE:20251112
DTSTAMP:20260515T025751
CREATED:20250613T091742Z
LAST-MODIFIED:20250613T091907Z
UID:41257-1762646400-1762905599@www.pharmajournalist.com
SUMMARY:8th Neuropsychiatric Drug Development Summit
DESCRIPTION:Industry’s Flagship Forum Capturing Advancements Across Discovery\, Preclinical\, Translational\, Clinical & Regulatory Development of Innovative Neuropsychiatric Therapeutics \nUniting 150+ discovery\, preclinical\, translational\, clinical\, and regulatory leaders\, the 8th Neuropsychiatric Drug Development Summit returns to provide you with an unrivaled opportunity to stay attuned to the latest progress while tackling industry’s most pressing challenges across a wide spectrum of mental health indications. \n \nRecognized by key leaders as the “ideal size”\, offering a “targeted audience” perfect for meaningful networking and collaboration\, join thought leaders from Bristol Myers Squibb\, AbbVie\, Otsuka\, Johnson & Johnson\, Biogen\, Lundbeck\, Delix Therapeutics\, Boehringer Ingelheim\, and many more this September to revitalize the mental health drug development landscape. \nOver the 3 day agenda\, you’ll engage in deep-dive interactive workshops\, roundtable discussions\, data-driven presentations and structured networking activities to foster collaboration and gain the latest insights to truly advance your pipeline of next generation neuropsychiatric therapeutics. \nOur attendees span discovery\, in vivo pharmacology\, translational medicine\, clinical development\, medical\, regulatory affairs\, academics\, venture capitalists\, and solution providers\, ensuring that whatever part you play in transforming the mental health treatment and therapeutic landscape\, you are surrounded by peers with the knowledge and capacity to support you. \nWhen you join the Neuropsychiatric Drug Development Summit you can expect to: \n\nDecipher the journey to ‘precision psychiatry’ through investigating the most progressive advancements in EEG and fluid-based markers\nDiscover innovative strategies to control placebo responses and bridge the translational gap to effectively analyze phenotypic behavior preclinically\nInvestigate the efficacy of standalone psychedelics vs when applied in conjunction with psychotherapy\, and explore groundbreaking progress in novel non-hallucinogenic neuroplastogens\nReview the latest advancements in new targets and mechanisms\, including moving beyond atypical antidepressants and antipsychotics\, to truly transform patient burdens\n\nPlus\, all new for 2025 is the EEG Focus Day which will support your efforts in utilizing EEG as a comprehensive and translational tool to guide your program through end-to-end development\, and the new Investor’s Panel which will explore the catalysts driving deal-making momentum in the current neuropsychiatric and mental health R&D landscape. \nSo\, what are you waiting for? Learn more about the summit today and explore the 40+ leading experts presenting at this year’s meeting\, the array of sessions and bespoke workshops designed to support you\, and the companies attending to advance neuropsychiatric therapeutics. \nView the brochure now for all this and more: https://ter.li/g4f9aj
URL:http://www.pharmajournalist.com/event/8th-neuropsychiatric-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR